Binding of Galectin-1 to Integrin β1 Potentiates Drug Resistance by Promoting Survivin Expression in Breast Cancer Cells

Overview

Journal Oncotarget

Specialty Oncology

Date 2017 Apr 19

PMID 28415760

Citations 30

Authors

KeeSoo Nam

Seog-Ho Son

Sunhwa Oh

Donghwan Jeon

Hyungjoo Kim

Dong-Young Noh

SangMin Kim

Incheol Shin

Affiliations

Soon will be listed here.

Abstract

Galectin-1 is a β-galactoside binding protein secreted by many types of aggressive cancer cells. Although many studies have focused on the role of galectin-1 in cancer progression, relatively little attention has been paid to galectin-1 as an extracellular therapeutic target. To elucidate the molecular mechanisms underlying galectin-1-mediated cancer progression, we established galectin-1 knock-down cells via retroviral delivery of short hairpin RNA (shRNA) against galectin-1 in two triple-negative breast cancer (TNBC) cell lines, MDA-MB-231 and Hs578T. Ablation of galectin-1 expression decreased cell proliferation, migration, invasion, and doxorubicin resistance. We found that these effects were caused by decreased galectin-1-integrin β1 interactions and suppression of the downstream focal adhesion kinase (FAK)/c-Src pathway. We also found that silencing of galectin-1 inhibited extracellular signal-regulated kinase (ERK)/signal transducer and activator of transcription 3 (STAT3) signaling, thereby down-regulating survivin expression. This finding implicates STAT3 as a transcription factor for survivin. Finally, rescue of endogenous galectin-1 knock-down and recombinant galectin-1 treatment both recovered signaling through the FAK/c-Src/ERK/STAT3/survivin pathway. Taken together, these results suggest that extracellular galectin-1 contributes to cancer progression and doxorubicin resistance in TNBC cells. These effects appear to be mediated by galectin-1-induced up-regulation of the integrin β1/FAK/c-Src/ERK/STAT3/survivin pathway. Our results imply that extracellular galectin-1 has potential as a therapeutic target for triple-negative breast cancer.

Citing Articles

Therapeutic Targeting of the Galectin-1/miR-22-3p Axis Regulates Cell Cycle and EMT Depending on the Molecular Subtype of Breast Cancer.

Kim J, Lee J, Jung E, Son Y, Park H, Kim J Cells. 2025; 14(4).

PMID: 39996781 PMC: 11854374. DOI: 10.3390/cells14040310.

Inhibition of Galectin-1 and Androgen Receptor Axis Enhances Enzalutamide Treatment in Enzalutamide Resistant Prostate Cancer.

Wang H, Gao A, Xia R, Wu C, Hsu S, Chen C Cancers (Basel). 2025; 17(3).

PMID: 39941722 PMC: 11816353. DOI: 10.3390/cancers17030351.

Advances in the Understanding of the Pathogenesis of Triple-Negative Breast Cancer.

Liu Y, Zou Y, Ye Y, Chen Y Cancer Med. 2024; 13(22):e70410.

PMID: 39558881 PMC: 11574469. DOI: 10.1002/cam4.70410.

Osteopontin is a therapeutic target that drives breast cancer recurrence.

Gu Y, Taifour T, Bui T, Zuo D, Pacis A, Poirier A Nat Commun. 2024; 15(1):9174.

PMID: 39448577 PMC: 11502809. DOI: 10.1038/s41467-024-53023-9.

Integrin β1 in breast cancer: mechanisms of progression and therapy.

Huang Q, Wang J, Ning H, Liu W, Han X Breast Cancer. 2024; 32(1):43-59.

PMID: 39343856 DOI: 10.1007/s12282-024-01635-w.

References

Isakoff S . Triple-negative breast cancer: role of specific chemotherapy agents. Cancer J. 2010; 16(1):53-61. PMC: 2882502. DOI: 10.1097/PPO.0b013e3181d24ff7. View

Kujawski M, Kortylewski M, Lee H, Herrmann A, Kay H, Yu H . Stat3 mediates myeloid cell-dependent tumor angiogenesis in mice. J Clin Invest. 2008; 118(10):3367-77. PMC: 2528912. DOI: 10.1172/JCI35213. View

Huang C, Tang S, Chung L, Yu C, Ho J, Cha T . Galectin-1 upregulates CXCR4 to promote tumor progression and poor outcome in kidney cancer. J Am Soc Nephrol. 2014; 25(7):1486-95. PMC: 4073433. DOI: 10.1681/ASN.2013070773. View

Zhang M, Zhang X, Zhao S, Wang Y, Di W, Zhao G . Prognostic value of survivin and EGFR protein expression in triple-negative breast cancer (TNBC) patients. Target Oncol. 2013; 9(4):349-57. DOI: 10.1007/s11523-013-0300-y. View

Mitra S, Schlaepfer D . Integrin-regulated FAK-Src signaling in normal and cancer cells. Curr Opin Cell Biol. 2006; 18(5):516-23. DOI: 10.1016/j.ceb.2006.08.011. View

Altieri D . Survivin, cancer networks and pathway-directed drug discovery. Nat Rev Cancer. 2007; 8(1):61-70. DOI: 10.1038/nrc2293. View

Niu G, Briggs J, Deng J, Ma Y, Lee H, Kortylewski M . Signal transducer and activator of transcription 3 is required for hypoxia-inducible factor-1alpha RNA expression in both tumor cells and tumor-associated myeloid cells. Mol Cancer Res. 2008; 6(7):1099-105. PMC: 2775817. DOI: 10.1158/1541-7786.MCR-07-2177. View

Hood J, Cheresh D . Role of integrins in cell invasion and migration. Nat Rev Cancer. 2003; 2(2):91-100. DOI: 10.1038/nrc727. View

Foulkes W, Smith I, Reis-Filho J . Triple-negative breast cancer. N Engl J Med. 2010; 363(20):1938-48. DOI: 10.1056/NEJMra1001389. View

10.

Kiuchi N, Nakajima K, Ichiba M, Fukada T, Narimatsu M, Mizuno K . STAT3 is required for the gp130-mediated full activation of the c-myc gene. J Exp Med. 1999; 189(1):63-73. PMC: 1887683. DOI: 10.1084/jem.189.1.63. View

11.

Li F, Altieri D . Transcriptional analysis of human survivin gene expression. Biochem J. 1999; 344 Pt 2:305-11. PMC: 1220645. DOI: 10.1042/0264-6021:3440305. View

12.

Soldati R, Berger E, Zenclussen A, Jorch G, Lode H, Salatino M . Neuroblastoma triggers an immunoevasive program involving galectin-1-dependent modulation of T cell and dendritic cell compartments. Int J Cancer. 2011; 131(5):1131-41. DOI: 10.1002/ijc.26498. View

13.

Shibue T, Weinberg R . Integrin beta1-focal adhesion kinase signaling directs the proliferation of metastatic cancer cells disseminated in the lungs. Proc Natl Acad Sci U S A. 2009; 106(25):10290-5. PMC: 2700942. DOI: 10.1073/pnas.0904227106. View

14.

Wen Z, Darnell Jr J . Mapping of Stat3 serine phosphorylation to a single residue (727) and evidence that serine phosphorylation has no influence on DNA binding of Stat1 and Stat3. Nucleic Acids Res. 1997; 25(11):2062-7. PMC: 146718. DOI: 10.1093/nar/25.11.2062. View

15.

Yadav B, Sharma S, Chanana P, Jhamb S . Systemic treatment strategies for triple-negative breast cancer. World J Clin Oncol. 2014; 5(2):125-33. PMC: 4014784. DOI: 10.5306/wjco.v5.i2.125. View

16.

Carpenter R, Lo H . STAT3 Target Genes Relevant to Human Cancers. Cancers (Basel). 2014; 6(2):897-925. PMC: 4074809. DOI: 10.3390/cancers6020897. View

17.

Tamm I, Wang Y, Sausville E, Scudiero D, Vigna N, Oltersdorf T . IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res. 1998; 58(23):5315-20. View

18.

Chakraborty A, White S, Guha S . Granulocyte colony-stimulating receptor promotes beta1-integrin-mediated adhesion and invasion of bladder cancer cells. Urology. 2006; 68(1):208-13. DOI: 10.1016/j.urology.2006.01.046. View

19.

Li F, Ambrosini G, Chu E, Plescia J, Tognin S, Marchisio P . Control of apoptosis and mitotic spindle checkpoint by survivin. Nature. 1998; 396(6711):580-4. DOI: 10.1038/25141. View

20.

Liedtke C, Mazouni C, Hess K, Andre F, Tordai A, Mejia J . Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol. 2008; 26(8):1275-81. DOI: 10.1200/JCO.2007.14.4147. View